TCM
LBRX

TCG Crossover Management’s LB Pharmaceuticals LBRX Stock Holding History

TCG Crossover Management’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$45.3M Buy
1,839,489
+94,474
+5% +$2.18M 1.3% 20
2025
Q4 		$38.8M Sell
1,745,015
-1
-0% -$17 1.29% 23
2025
Q3 		$27.6M Buy
+1,745,016
New +$27.7M 1.36% 22

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

TCG Crossover Management's LBRX Position: Q1 2026 in Review

TCG Crossover Management increased its LB Pharmaceuticals (LBRX) stake by 5.4% in Q1 2026, buying an estimated $2.18M and bringing the position to 1,839,489 shares worth $45.3M. The position accounts for 1.3% of the portfolio, ranked #20.

TCG Crossover Management first reported a position in LBRX in Q3 2025 and has held it in 3 quarters since. 77 funds tracked by Wall St. Rank hold LBRX as of Q1 2026.

  • TCG Crossover Management held 1,839,489 shares of LB Pharmaceuticals worth $45.3M as of Q1 2026.
  • TCG Crossover Management bought 94,474 LB Pharmaceuticals shares in Q1 2026, an estimated $2.18M.
  • LB Pharmaceuticals made up 1.3% of TCG Crossover Management's portfolio in Q1 2026, its #20 holding.
  • TCG Crossover Management first reported a position in LB Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 77 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q1 2026.

Based on TCG Crossover Management's 13F filing for Q1 2026, filed 15 May 2026.